0000921895-26-001100.txt : 20260428 0000921895-26-001100.hdr.sgml : 20260428 20260428173945 ACCESSION NUMBER: 0000921895-26-001100 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260422 FILED AS OF DATE: 20260428 DATE AS OF CHANGE: 20260428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lazar David E. CENTRAL INDEX KEY: 0001932843 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41010 FILM NUMBER: 26909539 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 44, TOWER 100, THE TOWERS STREET 2: WINSTON CHURCHILL, PAITILLA CITY: PANAMA CITY PROVINCE COUNTRY: R1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quantum Cyber N.V. CENTRAL INDEX KEY: 0001874252 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: ROBERT KOCH STRASSE 50 CITY: MAINZ PROVINCE COUNTRY: 2M BUSINESS PHONE: 49 6131 5542860 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: ROBERT KOCH STRASSE 50 CITY: MAINZ PROVINCE COUNTRY: 2M FORMER COMPANY: FORMER CONFORMED NAME: MAINZ BIOMED N.V. DATE OF NAME CHANGE: 20211112 FORMER COMPANY: FORMER CONFORMED NAME: Mainz Biomed B.V. DATE OF NAME CHANGE: 20210721 4 1 form412227qucy_04232026.xml OWNERSHIP DOCUMENT X0609 4 2026-04-22 0 0001874252 Quantum Cyber N.V. MYNZ 0001932843 Lazar David E. true 44, TOWER 100, THE TOWERS WINSTON CHURCHILL, PAITILLA PANAMA CITY PANAMA R1 07196 PANAMA 1 1 1 0 Chief Executive Officer 0 Ordinary Shares 0 D Series D Preferred Shares 2026-04-22 4 A 0 1000000 1.50 A 2026-04-22 Ordinary Shares 225000000 1000000 D Series E Preferred Shares 2026-04-22 4 A 0 1000000 1.50 A 2026-04-22 Ordinary Shares 225000000 1000000 D No ordinary shares are beneficially owned. As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares. The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration. Each class of Preferred Stock is perpetual and therefore has no expiration date. /s/ David E. Lazar 2026-04-28